Lonza
Lonza is a leading CDMO for bioconjugates, supporting over 100 ADC programs since 2006. Our integrated offering spans from late discovery to commercial manufacturing, leveraging deep expertise across small molecules, mammalian and microbial systems, and bioconjugate drug candidates.
Through the acquisition of Synaffix and its clinical stage ADC technology platform along with our continued investment in large-scale manufacturing and drug product filling, we help customers bring innovative therapies to patients efficiently, safely, and at scale.
